Paper42889618PubMed
Repurposing of Milciclib as a Potential Inhibitor of Toxoplasma gondii in Human Trophoblasts and Placental Explants.
de Oliveira RM and 14 others. ACS Omega, 2026.
Cite this record
ConductScience Library. Repurposing of Milciclib as a Potential Inhibitor of Toxoplasma gondii in Human Trophoblasts and Placental Explants. Papers, record 42889618. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42889618
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Repurposing of Milciclib as a Potential Inhibitor of Toxoplasma gondii in Human Trophoblasts and Placental Explants.
- Journal
- ACS Omega
- Year
- 2026
- Publication types
- Journal Article
- Revised in PubMed
- 2026-10-19
Source PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References43
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 36613575 | The Update Immune-Regulatory Role of Pro- and Anti-Inflammatory Cytokines in Recurrent Pregnancy Losses. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/36613575 | PubMed |
| 2 | 31024205 | Hepatocellular Carcinoma: Etiology and Current and Future Drugs. | J Clin Exp Hepatol | 2019 | https://conductscience.org/library/papers/31024205 | PubMed |
| 3 | 40892525 | Two-Dimensional Dissipative Paper-Based Immunoassay with Oxygen Vacancy-Enriched CeO2 Nanozymes for Portable Cancer Screening. | Anal Chem | 2025 | https://conductscience.org/library/papers/40892525 | PubMed |
| 4 | 29133550 | Discovery of New Inhibitors of Toxoplasma gondii via the Pathogen Box. | Antimicrob Agents Chemother | 2018 | https://conductscience.org/library/papers/29133550 | PubMed |
| 5 | 30041005 | Congenital toxoplasmosis: An overview of the neurological and ocular manifestations. | Parasitol Int | 2018 | https://conductscience.org/library/papers/30041005 | PubMed |
| 6 | 28424962 | Phase I dose-escalation study of milciclib in combination with gemcitabine in patients with refractory solid tumors. | Cancer Chemother Pharmacol | 2017 | https://conductscience.org/library/papers/28424962 | PubMed |
| 7 | 38724467 | Role of maternal-fetal immune tolerance in the establishment and maintenance of pregnancy. | Chin Med J (Engl) | 2024 | https://conductscience.org/library/papers/38724467 | PubMed |
| 8 | 37722575 | Rottlerin impairs early and late steps of Toxoplasma gondii infection in human trophoblast cells and villous explants. | Chem Biol Interact | 2023 | https://conductscience.org/library/papers/37722575 | PubMed |
| 9 | 32095620 | Environmental transmission of Toxoplasma gondii: Oocysts in water, soil and food. | Food Waterborne Parasitol | 2019 | https://conductscience.org/library/papers/32095620 | PubMed |
| 10 | 41415569 | Novel drug candidates targeting Toxoplasma gondii in maternal-fetal interface models. | Front Pharmacol | 2025 | https://conductscience.org/library/papers/41415569 | PubMed |
| 11 | 20682657 | Dual targeting of CDK and tropomyosin receptor kinase families by the oral inhibitor PHA-848125, an agent with broad-spectrum antitumor efficacy. | Mol Cancer Ther | 2010 | https://conductscience.org/library/papers/20682657 | PubMed |
| 12 | 26976749 | Oxidative stress generated during monensin treatment contributes to altered Toxoplasma gondii mitochondrial function. | Sci Rep | 2016 | https://conductscience.org/library/papers/26976749 | PubMed |
| 13 | 39304928 | STK40 inhibits trophoblast fusion by mediating COP1 ubiquitination to degrade P57Kip2. | J Transl Med | 2024 | https://conductscience.org/library/papers/39304928 | PubMed |
| 14 | 21098240 | The antibiotic monensin causes cell cycle disruption of Toxoplasma gondii mediated through the DNA repair enzyme TgMSH-1. | Antimicrob Agents Chemother | 2011 | https://conductscience.org/library/papers/21098240 | PubMed |
| 15 | 39265235 | Copaifera spp. oleoresins control Trypanosoma cruzi infection in human trophoblast cells (BeWo) and placental explants. | Biomed Pharmacother | 2024 | https://conductscience.org/library/papers/39265235 | PubMed |
| 16 | 35422792 | Different Drugs, Same End: Ultrastructural Hallmarks of Autophagy in Pathogenic Protozoa. | Front Microbiol | 2022 | https://conductscience.org/library/papers/35422792 | PubMed |
| 17 | 34254575 | Congenital toxoplasmosis in humans: an update of worldwide rate of congenital infections. | Parasitology | 2021 | https://conductscience.org/library/papers/34254575 | PubMed |
| 18 | 40284561 | Treatment Protocols for Gestational and Congenital Toxoplasmosis: A Systematic Review and Meta-Analysis. | Microorganisms | 2025 | https://conductscience.org/library/papers/40284561 | PubMed |
| 19 | 39254212 | D-Band-Center-Engineered Platinum-Based Nanozyme for Personalized Pharmacovigilance. | Angew Chem Int Ed Engl | 2025 | https://conductscience.org/library/papers/39254212 | PubMed |
| 20 | 30861423 | Increased ROS generation causes apoptosis-like death: Mechanistic insights into the anti-Leishmania activity of a potent ruthenium(II) complex. | J Inorg Biochem | 2019 | https://conductscience.org/library/papers/30861423 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42889618
GET https://conductscience.org/api/papers/v1/42889618/references?page=2